Aardvark Therapeutics Reports Exploratory Phase 3 HERO And OLE Data Showing Rapid Hunger Score Reductions With ARD-101 In PWS, FDA Lifts Clinical Hold And Company Targets New Phase 3 Trial
HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two
Aardvark's hunger medicine showed quick results in early testing. The FDA let them keep testing, which means the drug passed a safety checkpoint and the company can move forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.